Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scopolamine for Bipolar Depression (SCOPE-BD)
NCT04211961Phase 2Completed
- Start
- Mar 2021
- Primary completion
- Feb 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing Placebo with Scopolamine (2 arms). Primary endpoint: Hamilton Depression Rating Scale at 2 weeks. Started Mar 2021; status: completed.
02
Drugs
scopolamine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT04211961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211961.